Federal agency priorities under the Biden Administration
To listen to all PwC Next in Health podcasts, click here. Subscribe and listen to all episodes at your convenience via any device at Apple Podcasts, Spotify and Stitcher.
Overview
Tune into this episode of PwC's Next in Health to hear Health Research Institute (HRI) leader, Benjamin Isgur, and HRI Regulatory Center leader, Trine Tsouderos in discussion with HRI's Erin McCallister on what pharma might expect from federal agencies, including:
- Food and Drug Administration (FDA)'s potential to broaden / standardized policies implemented in response to the pandemic (i.e., clinical trial diversity, supply chain visibility)
- How politics has impacted FDA productivity
- Centers for Medicare & Medicaid Services (CMS)' approach to control drug spending
- Health and Human Services' role in 340B changes
Topics: Federal agency policies, clinical trials, medical supply chain, controlled drug spending
Contact us
Follow us
